In an exclusive interview, Bayer’s global head of pharmaceuticals, Stefan Oelrich, said the company will intensify its push for tiered pricing in India. The move is linked to Bayer’s “tailormade India” portfolio and its broader investment plans in innovation, aiming to balance affordability with business sustainability.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
